Back to Startups

Tres Alchemix

Bioscience & Disease AI, ML, Gen AI Deep Tech
Bioscience & Disease AI, ML, Gen AI Deep Tech Show less
Bioscience & Disease AI, ML, Gen AI +1
Bioscience & Disease AI, ML, Gen AI Deep Tech Show less
@TresAlchemix Website LinkedIn San Francisco, California, USA
About Tres Alchemix

An early-stage biotechnology company applying artificial intelligence (AI) to drug discovery.

Business Information
Target Customers
pharmaceutical companies research institutions biotech firms
Industry Categories
Bioscience & Disease AI, ML, Gen AI Deep Tech
Business Model
Revenue Model B2B partnerships and licensing
Pricing Strategy Project-based pricing and milestone payments
Sales Channels direct sales, partnerships with research institutions
Funding Timeline
Round Date Amount Investors
Series A Oct 03, 2023 $4.4M DNX Ventures, Waseda
Founders

No founder information available.

Investors
D
DNX Ventures

Venture Capital

W
Waseda

Venture Capital

Recent Mentions
pressat
Pressat @pressat
Oct 02, 2025

Tres Alchemix, an early-stage biotechnology company applying artificial intelligence (AI) to drug discovery, today announced it has closed a $4.4 million [¥650 million] Series A financing. The round was led by DNX Ventures, with participation from existing investor Waseda

View on Twitter
Similar Startups
AltrixBio
89% match

AltrixBio is a biotechnology startup focused on developing innovative solutions in the field of life...
DistylAI
89% match

Accelerating pharmaceutical R&D with predictive AI models.
Alex
88% match

Alex is an innovative startup focused on leveraging artificial intelligence to provide cutting-edge ...
ArcaScienceEU
88% match

The AI healthtech startup transforms drug development by turning unstructured biomedical data into c...